

Metabolic Consequences of Adenosine Deaminase Deficiency in Mice Are Associated with Defects in Alveogenesis, Pulmonary Inflammation, and Airway Obstruction

By Michael R. Blackburn,* Jonathan B. Volmer,* Janci L. Thrasher,*
Hongyan Zhong,* Jeff R. Crosby,[‡] James J. Lee,[‡]
and Rodney E. Kellems*

From the *Department of Biochemistry and Molecular Biology, University of Texas Health Science Center at Houston Medical School, Houston, Texas 77030; and the [‡]Department of Biochemistry and Molecular Biology, Mayo Clinic, Scottsdale, Arizona 85259

Abstract

Adenosine deaminase (ADA) is a purine catabolic enzyme that manages levels of the biologically active purines adenosine and 2'-deoxyadenosine in tissues and cells. ADA-deficient mice die at 3 wk of age from severe respiratory distress. This phenotype is progressive and is linked to perturbations in pulmonary purine metabolism. The inflammatory changes found in the lungs of ADA-deficient mice included an accumulation of activated alveolar macrophages and eosinophils. These changes were accompanied by a pronounced enlargement of alveolar spaces and increases in mucus production in the bronchial airways. The alveolar enlargement was found to be due in part to abnormal alveogenesis. Lowering adenosine and 2'-deoxyadenosine levels using ADA enzyme therapy decreased the pulmonary eosinophilia and resolved many of the lung histopathologies. In addition, genetically restoring ADA to the forestomach of otherwise ADA-deficient mice prevented adenine metabolic disturbances as well as lung inflammation and damage. These data suggest that disturbances in purinergic signaling mediate the lung inflammation and damage seen in ADA-deficient mice.

Key words: eosinophil • asthma • emphysema • alveolar macrophage • adenosine deaminase

Introduction

Adenosine deaminase (ADA)¹ is an essential enzyme of purine catabolism that is responsible for the hydrolytic deamination of adenosine and 2'-deoxyadenosine to inosine and 2'-deoxyinosine (1). These biochemical pathways are essential for maintaining homeostasis, as both ADA substrates have substantial signaling properties. Adenosine engages G protein-coupled receptors on the surface of target cells to evoke a variety of cellular responses (2), whereas 2'-deoxyadenosine is cytotoxic via mechanisms that interfere with cellular growth and differentiation (3, 4) or the promotion

of apoptosis (5, 6). ADA deficiency in humans results in marked accumulations of both of these signaling molecules, and these accumulations are associated with a variety of cellular phenotypes. The most thoroughly studied phenotype has been the effect of this enzyme deficiency on the immune system. ADA deficiency results in a combined immunodeficiency characterized by a severe T, B, and NK cell lymphopenia (7, 8). Most studies identify the accumulation of 2'-deoxyadenosine as the metabolic basis for this lymphopenia (3, 9), although evidence exists to suggest that engagement of adenosine receptors may be involved (10, 11). Additional phenotypes associated with ADA deficiency are not as well characterized and include bony and renal abnormalities (12), hepatocellular damage (13), neurological disorders (14), and pulmonary insufficiency (7). The metabolic basis for these phenotypes and the mechanisms involved are unknown, in part due to the lack of adequate models with which to study the effects of ADA deficiency on these systems.

Address correspondence to Michael R. Blackburn, University of Texas Health Science Center at Houston Medical School, Department of Biochemistry and Molecular Biology, 6431 Fannin St., Houston, TX 77030. Phone: 713-500-6087; Fax: 713-500-0652; E-mail: michael.r.blackburn@uth.tmc.edu

¹Abbreviations used in this paper: ADA, adenosine deaminase; BALF, bronchial alveolar lavage fluid; H&E, hematoxylin and eosin; mMBP-1, murine eosinophil granule major basic protein 1; PAS, periodic acid-Schiff; PEG, polyethylene glycol.

We have recently used a two-stage genetic engineering strategy to generate ADA-deficient mice (15). The initial knockout of the murine *Ada* gene resulted in a prenatal lethality that prevented the analysis of postnatal consequences of ADA deficiency (16, 17). This prenatal lethality was overcome with an ADA minigene under the control of a trophoblast-specific promoter to restore ADA specifically to the placenta of otherwise ADA-deficient fetuses (15, 18). This was sufficient to rescue ADA-deficient fetuses and resulted in postnatal ADA-deficient mice amenable to the analysis of the phenotypic and metabolic consequences of ADA deficiency. ADA-deficient mice developed a combined immunodeficiency that was linked with profound disturbances in purine metabolism (15, 19).

In addition to immunodeficiency, ADA-deficient mice developed other phenotypes noted in ADA-deficient humans (12), including bony and renal abnormalities and pulmonary insufficiency (15). The most severe of these phenotypes was the pulmonary insufficiency. ADA-deficient mice began to show signs of respiratory distress as early as postpartum day 12. This distress increased in severity, and the mice died between postpartum days 19 and 25. Initial examination of this phenotype revealed severe lung inflammation in association with severe purine metabolic disturbances including the accumulation of adenosine and to a lesser extent 2'-deoxyadenosine (15).

Purinergic signaling has been implicated to play a role in lung inflammation. Most notable are the well-recognized effects of adenosine in asthma (20). Clinical evidence linking adenosine to this disease state includes the detection of elevated adenosine levels in bronchial alveolar lavage fluid (BALF) collected from asthmatics (21); the observation that inhaled adenosine elicits bronchoconstriction in individuals suffering from asthma (22); the expression of adenosine receptors is altered in patients with airway inflammation (23); and theophylline, an adenosine receptor antagonist, has a well-recognized therapeutic benefit in this disease (24). In addition, there are many *in vitro* studies that implicate adenosine as a modulator of inflammatory processes that are central to asthma. These include adenosine's ability to enhance (25) or directly evoke (26) mediator release from mast cells, and to influence eosinophil function (27–29). Adenosine signaling has also been implicated in regulating the function of other inflammatory cells such as macrophages (30–32) and neutrophils (33, 34). Despite these lines of evidence, a causative link between adenosine signaling and lung inflammation, as well as the cell types and mechanisms involved, are unclear. In the current study, we characterized the lung inflammation and damage occurring in ADA-deficient mice. Moreover, we used ADA enzyme therapy to demonstrate a relationship between adenosine and 2'-deoxyadenosine levels and the inflammation that results in ADA-deficient animals. The ADA-deficient mice described exhibited many features of lung disease, including defects in alveogenesis, activation of alveolar macrophages, lung eosinophilia, and mucus hypersecretion. These pulmonary features were closely associated with disturbances in the concentrations of ADA substrates, suggesting that perturbations

in signaling pathways accessed by these substrates are involved. This model will provide a unique approach to examining the specific roles of adenosine signaling *in vivo*.

Materials and Methods

Transgenic Mice. ADA-deficient mice were generated and genotyped as described previously (15, 16). All mice used in these studies were on a mixed background of 129/Sv and FVB/N strains (18). Control mice were either wild-type animals or mice heterozygous for the null *Ada* allele (15). Animal care was in accordance with institutional and National Institutes of Health guidelines. All mice were housed in cages equipped with microisolator lids and maintained under strict containment protocols. No evidence of bacterial, parasitic, or fungal infection was found. In addition, serologies on cage littermates were negative for 12 of the most common murine viruses.

Histological Analysis and Immunofluorescence. Aged-matched control and experimental animals were killed, and the lungs were infused with 0.1–0.5 ml of fixative (4% paraformaldehyde in PBS), depending on age, before fixation overnight at 4°C. Fixed lung samples were rinsed in PBS, dehydrated, and embedded in paraffin. Sections (5 μ m) were collected on microscope slides and stained with hematoxylin and eosin (H&E; Shandon-Lipshaw) or periodic acid-Schiff (PAS; EM Science), according to manufacturer's instructions. Immunofluorescence of lungs for the expression of murine eosinophil granule major basic protein 1 (mMBP-1) was performed according to established procedures (35). Sections were reacted with antiserum from a rabbit immunized with purified mMBP-1, followed by detection using FITC-conjugated anti-rabbit IgG.

Quantification of Lung Histopathology. The size of alveolar airways was determined by measuring mean chord lengths (36) on H&E-stained lungs. Representative images were digitized, and a grid consisting of 53 black lines at 10.5- μ m intervals was overlaid on the image. This line grid was subtracted from the lung images using Image-Pro® Plus (Media Cybernetics) image analysis software, and the resultant lines were measured and averaged to give the mean chord length of the alveolar airways. The final mean chord lengths represent averages from 12 nonoverlapping images of each lung specimen and are given in micrometers.

The extent of mucus production in bronchial airways was determined by quantitating the amount of PAS-stained material in the bronchial airways using Image-Pro® Plus analysis software. PAS-stained material was identified on digitized images, and the pixel intensities of each color channel (red, blue, and green) were averaged. This was repeated for each image, and the values were averaged and used to determine the area (*M*) and intensity (*I*) of PAS-stained material in bronchial airways. In addition, the area (*A*) of the total epithelium (including PAS-stained material) was determined. The mucus index was determined using the following equation: $M \times I/A$. Final indices were results of an average of eight images per lung encompassing large and small bronchial airways.

Peripheral Blood Cell Counts. Mice were anesthetized, and a heparinized syringe was used to collect 200–500 μ l of blood from the subaxillary artery. Samples were immediately analyzed for complete blood cell counts using an H1 Analyzer (Technicon Instruments).

Bronchial Alveolar Lavages. Mice were anesthetized with avertin, and a blunted 21-gauge needle was secured into the trachea. Lungs were lavaged five times with 0.25 ml PBS, and 0.95–1 ml of pooled lavage fluid was recovered. Samples were centrifuged at

2,500 rpm for 5 min to recover cells, and supernatant from these spins was collected and stored at -70°C for the analysis of cytokines. BALF cells were resuspended in $200\ \mu\text{l}$ PBS; total cell counts were determined from an aliquot counted using a hemocytometer, and another aliquot cytospun onto microscope slides was stained with Diff-Quik (Dade) for cellular differentials. 400 cells per sample were identified and counted under oil immersion.

ELISA Assays. IFN- γ , IL-4, and IL-5 levels in BALF were determined using specific murine OptEIA™ ELISA kits from BD PharMingen. For the analysis of IgE levels, blood was collected from the heart of anesthetized mice and the serum was separated by centrifugation at 3,000 rpm for 10 min at 4°C . A murine OptEIA ELISA kit from BD PharMingen was used to quantitate total serum IgE levels.

ADA Enzyme Therapy and Analysis of ADA Enzyme Activity. Polyethylene glycol-modified ADA (PEG-ADA), also known as ADAGEN®, was obtained through collaboration with Enzon, Inc. Control or ADA-deficient mice were anesthetized and injected intramuscularly with $10\ \mu\text{l}$ of PEG-ADA corresponding to $\sim 2.5\ \text{U}$ of ADA enzymatic activity. Injections were given either chronically every 4 d starting at postpartum day 4, or acutely, as one in-

jection on postpartum day 18. Levels of ADA enzyme activity in tissues were measured according to established procedures (15).

Quantification of Adenosine and 2'-Deoxyadenosine. Mice were anesthetized, the thoracic cavity was exposed, and the lungs were removed and frozen rapidly in liquid nitrogen. Adenine nucleosides were extracted from frozen lungs using $0.4\ \text{N}$ perchloric acid as described (37), and adenosine and 2'-deoxyadenosine were separated and quantitated using reversed phase HPLC (37).

Results

Severe Lung Inflammation and Damage Are Found in the Lungs of ADA-deficient Mice. ADA-deficient mice begin to show signs of respiratory distress as early as postpartum day 12. This distress was characterized by rapid and labored breathing that became increasingly severe. These mice became cyanotic and died between postpartum days 19 and 25 (15). Lung inflammation was examined on postpartum day 18 to assess the nature of the respiratory distress in ADA-deficient mice (Fig. 1). An increase in inflammatory




Figure 1. Morphological and cytological changes in the lungs of ADA-deficient mice. (a) H&E-stained control lung at postpartum day 18. (b) H&E-stained ADA-deficient lung at postpartum day 18. Arrows indicate areas of inflammation. Notice the pronounced enlargement of alveolar spaces (AS) and the thickening of pulmonary blood vessels (BV). (c) High magnification of an H&E-stained ADA-deficient lung demonstrating eosinophil infiltration (arrows) around bronchioles (B) and pulmonary blood vessels (BV). (d) Immunolocalization of eosinophils in an 18-d-old ADA-deficient lung, using a rabbit polyclonal antibody raised against mMBP-1 followed by detection with FITC immunofluorescence. Notice intense staining of inflammatory cells with anti-MBP-1 (arrows). mMBP-1 immunoreactivity was also detected in alveolar macrophages (AM). Cytological analysis of cells collected from BALF from the lung of an 18-d-old ADA-deficient mouse showing (e) eosinophils (arrows), (f) alveolar macrophages engulfing eosinophils (arrows), and (g) multinucleated giant cells. Bars, (a-d) $100\ \mu\text{m}$; (e-g) $10\ \mu\text{m}$.

Table I. Peripheral Blood Cell Counts

	<i>n</i>	RBC*	WBC [†]	Lymphocyte [§]	Monocyte [§]	Eosinophil [§]	Neutrophil [§]
Control	5	6.95 ± 0.2	1,564 ± 179	1,138 ± 134	170 ± 42	22 ± 7	238 ± 66
ADA-deficient	4	6.38 ± 0.2	1,263 ± 156	563 ± 48	225 ± 100	48 ± 8 [†]	385 ± 111
ADA-deficient +PEG-ADA	3	6.17 ± 0.2	1,187 ± 396	623 ± 107	207 ± 162	23 ± 12 ^{**}	303 ± 151

Peripheral blood cell counts are from 18-d-old control and ADA-deficient mice or ADA-deficient mice 72 h after a single dose of PEG-ADA on day 18.

*Mean red blood cells $\times 10^6 \pm$ SE.

[†]Mean white blood cells $\times 10^6 \pm$ SE.

[§]Cells/ml \pm SE.

^{||}Statistically different from control ($P \leq 0.005$) using a two sample *t* test assuming unequal variance.

[†]Statistically different from control ($P \leq 0.02$) using a two sample *t* test assuming unequal variance.

^{**}Statistically different from ADA-deficient ($P \leq 0.05$) using a two sample *t* test assuming unequal variance.

cells was seen throughout the lungs, with a specific increase of enlarged and foamy macrophages (Fig. 1 b). Closer examination of cells collected from BALF showed alveolar macrophages engulfing eosinophils (Fig. 1 f). In addition, multinucleated giant cells were prominent in the BALF (Fig. 1 g). Histological analysis also suggested a pronounced infiltration of eosinophils throughout the lungs (Fig. 1, b and c, arrows). Lung sections were reacted with a polyclonal antibody against mMBP-1 (35) to confirm that the cells were eosinophils. Results from these studies (Fig. 1 d) confirm the accumulation of eosinophils in ADA-deficient lungs. Eosinophils were found in interstitial and luminal spaces throughout the lung, with high concentrations accumulating around bronchioles and pulmonary blood vessels (Fig. 1, b–d, arrows). Intense mMBP-1 immunoreactivity was noted in alveolar macrophages surrounding focal points of eosinophil accumulation (Fig. 1 d, yellow arrows), confirming the engulfment of eosinophils by activated macrophages. A large increase in eosinophils was also found in BALF (Fig. 1 e), and there was a twofold increase in circulating eosinophils (Table I). Inflammation was not seen in other tissues that were examined, including the gastrointestinal tract, thymus, spleen, liver, and kidney (data not shown). These results demonstrated that ADA-deficient

mice developed pronounced pulmonary inflammation characterized by the accumulation of activated alveolar macrophages and eosinophils.

Evidence of tissue damage and lung remodeling accompanied the inflammatory changes in ADA-deficient lungs. Examination of the alveolar airways demonstrated a prominent increase in the size of alveolar spaces as well as increases in the thickness of the smooth muscle of pulmonary blood vessels (Fig. 1 b). Hypertrophy of the bronchial epithelium was common, as was a progressive increase in mucus production and an accumulation of mucus and cellular debris in the bronchial airways (Fig. 2). Collectively, these results demonstrated that the pulmonary inflammation seen in ADA-deficient mice was associated with histopathological changes in the lung.

Developmental Defects in Alveogenesis Precede Lung Inflammation in ADA-deficient Mice. The severe inflammation and damage seen on day 18 prompted us to examine the development of this phenotype. At birth, control and ADA-deficient lungs were histologically similar (Fig. 3, a and b). At postpartum day 5, the overall morphology (Fig. 3, c and d) suggested that there was an increase in alveolar airway size. Secondary septation of the alveoli occurred between postpartum days 5 and 10 in control mice (Fig. 3 e);




Figure 2. Mucus hypersecretion in the bronchial airways of ADA-deficient mice. Lung sections were stained with PAS for the detection of neutral mucins. (a) Control lung at postpartum day 18. (b) ADA-deficient lung at postpartum day 18. (c) ADA-deficient lung at postnatal day 21. Arrows in b and c denote PAS-positive material indicative of increased mucus production. B, bronchiole. Bars, 100 μ m.

however, alveolar size remained enlarged in ADA-deficient lungs at postpartum day 10 (Fig. 3 f). Quantitation of alveolar size (Fig. 3 g) verified that there was a significant difference in alveolar size at day 5, suggesting that alveolar formation in ADA-deficient mice was disturbed early in life and worsened by day 10. Lung inflammation was not seen in ADA-deficient lungs at day 0 and day 5 as determined by H&E staining (Fig. 3) and mMBP-1 immunostaining (data not shown). Slight inflammation was seen at day 10 (Fig. 3 f), and increased numbers of alveolar macrophages and eosinophils were consistently seen at day 15 (data not shown; 15). These results demonstrated that there was a defect in alveogenesis in ADA-deficient mice and that these defects preceded the appearance of lung inflammation.

Serum IgE and BALF IL-5 Levels Are Elevated in ADA-deficient Mice. Elevated IgE and eosinophilia are features noted in some subsets of ADA-deficient patients (8, 38, 39). Total serum IgE levels were assessed to determine whether elevations in IgE were associated with the lung eosinophilia seen in ADA-deficient mice. Serum IgE levels

were slightly increased on postpartum day 18 (Fig. 4 a); however, when the ratios of IgE to total Ig were compared in control and ADA-deficient mice (Fig. 4 b), a prominent bias towards IgE production was seen in ADA-deficient animals.

Cytokine levels in BALF of 18-d-old ADA-deficient mice were examined to investigate whether the lung inflammation seen was associated with a Th2 cytokine profile. Though there was a trend toward a reduction in the levels of IFN- γ in ADA-deficient BALF, the differences were not significant (Fig. 4 c). There was no difference in the levels of IL-4 in ADA-deficient BALF; however, slight increases in IL-5 were noted (Fig. 4 c). These findings suggested that IL-5 signaling may be involved in the eosinophilia seen in ADA-deficient mice.

ADA Enzyme Therapy Results in the Reduction of BALF and Circulating Eosinophils and a Decrease in Mucus Production by Bronchial Airways. PEG-ADA enzyme therapy is a lifesaving strategy used to treat ADA-deficient patients (40). ADA-deficient mice maintained on weekly injections of PEG-ADA from birth did not show signs of ab-




Figure 3. Defects in alveogenesis in ADA-deficient mice. Lungs from age-matched control and ADA-deficient mice were collected and processed for H&E staining. (a) Control lung at postpartum day 0. (b) ADA-deficient lung at day 0. (c) Control lung at day 5. (d) ADA-deficient lung at day 5. (e) Control lung at day 10 demonstrating the septation of presumptive alveoli into mature alveolar sacs. (f) ADA-deficient lung at day 10 demonstrating enlarged alveolar spaces. Panels a-f are at the same magnification; bars, 250 μm . (g) The size of alveolar airways was determined in control (white bars, $n = 4$) and ADA-deficient (black bars, $n = 4$) lungs by measuring mean chord lengths (in μm) of alveolar airways in H&E-stained lungs. Values are given as mean $\mu\text{m} \pm$ SE from four separate age-matched control and ADA-deficient lung pairs at each developmental stage; * $P \leq 0.05$.




Figure 4. Levels of serum IgE and BALF cytokines in control (white bars) and ADA-deficient (black bars) mice. (a) Total IgE levels were measured in the serum of 18-d-old control ($n = 11$) and ADA-deficient ($n = 8$) mice. Mean total serum IgE values are given as $\text{ng/ml} \pm \text{SE}$. Total serum Ig [IgG + IgM] levels are decreased 67% in ADA-deficient mice (reference 15). (b) Ratios of IgE to Ig in control and ADA-deficient mice, demonstrating a significant bias towards hyper IgE in ADA-deficient mice. Statistical significance was determined using Student's t test analysis; $*P \leq 0.100$, $**P \leq 0.05$. (c) The levels of IFN- γ , IL-4, and IL-5 were measured in BALF collected from 18-d-old control ($n = 10$) and ADA-deficient ($n = 7$) mice. Mean values are given as $\text{pg/ml} \pm \text{SE}$.

normal alveogenesis, lung eosinophilia, or respiratory distress, and survived as long as they were maintained on PEG-ADA (data not shown). To determine if PEG-ADA treatments could reverse the pulmonary phenotype after its onset, ADA-deficient mice were allowed to develop severe lung inflammation (day 18) and were subsequently treated with PEG-ADA. Within 24–48 h, their respiratory status was noticeably improved, and these animals recovered and survived as long as they were maintained on PEG-ADA (data not shown). Cell populations were monitored in BALF collected 72 h after treatment with PEG-ADA to determine what effect PEG-ADA treatment had on lung inflammation (Fig. 5). The most striking observation was a substantial decrease in the number of eosinophils in BALF of ADA-deficient mice treated with PEG-ADA. The numbers of alveolar macrophages were not reduced at 72 h after PEG-ADA treatment, but were reduced after 2 wk of enzyme therapy (Fig. 5). These findings suggested that PEG-ADA enzyme therapy led to a rapid reduction in lung eosinophilia in ADA-deficient mice.

ADA-deficient mice are lymphopenic, showing a two- to threefold reduction in the number of circulating lymphocytes (15). Complete blood cell counts were assessed in




Figure 5. Reversible lung eosinophilia in ADA-deficient mice treated with PEG-ADA. Total cellular differentials were determined on cells collected from BALF of 18-d-old control mice ($n = 19$, white bars), ADA-deficient mice ($n = 12$, black bars), and ADA-deficient mice treated with PEG-ADA and examined 3 d later ($n = 5$, hatched bars) or after 2 wk of enzyme therapy ($n = 4$, stippled bars). Mean values are given as total cells $\pm \text{SE}$. Statistical significance was determined using Student's t test analysis; $*P \leq 0.02$.

ADA-deficient mice and ADA-deficient mice treated with PEG-ADA to determine if the improvement in lung inflammation was related to an improvement in lymphocyte counts. There was a twofold decrease in the number of lymphocytes seen in the periphery of ADA-deficient mice (Table I); however, there was not a significant improvement in the number of lymphocytes found in the circulation after PEG-ADA treatment. There was a twofold elevation in the number of peripheral eosinophils in ADA-deficient mice, and peripheral eosinophil numbers were normalized after PEG-ADA treatment. These data suggested that the PEG-ADA treatments used in this study did not have a significant impact on the lymphopenia seen in ADA-deficient mice, but were capable of reducing elevations in lung and circulating eosinophils.

The amount of alveolar and bronchial tissue damage was quantitated before and after PEG-ADA treatments to determine what effect PEG-ADA treatments had on this damage. The severe alveolar defect seen in ADA-deficient mice was not significantly improved 72 h after treatment with PEG-ADA (Fig. 6 a). In contrast, the mucus production seen in the bronchial airways was substantially lower 72 h after PEG-ADA treatments (Fig. 6 b). Collectively, these results suggested that restoring ADA enzymatic activity to ADA-deficient mice decreased the number of eosinophils found in BALF and attenuated mucus production in bronchial airways, but did not reverse the abnormal lung structure resulting from abnormal alveogenesis and lung inflammation.

Treatment of ADA-deficient Mice with PEG-ADA Results in Normalization of Lung Adenine Nucleoside Levels. The elevated levels of adenosine, and to a lesser extent 2'-deoxyadenosine, in the lungs of ADA-deficient mice (15) suggested that pulmonary inflammation observed in these mice was due to disturbances in adenine metabolism. The rapid reversal of respiratory distress and lung eosinophilia




Figure 6. Quantification of lung histopathology in ADA-deficient mice and ADA-deficient mice treated with PEG-ADA. (a) Mean cord lengths of alveolar airways were determined in lungs of 18-d-old control and ADA-deficient mice, and lungs of 21-d-old mice 72 h after treatment with PEG-ADA. Values are given as mean cord lengths in $\mu\text{m} \pm \text{SE}$, $n = 5$ for each condition. $*P \leq 0.02$ for increases in mean cord lengths compared with controls. (b) The degree of mucus production was determined in the bronchial airways of 18-d-old control and ADA-deficient mice, and 21-d-old ADA-deficient mice 3 d after treatment with PEG-ADA. Values are given as mean airway mucus indices in arbitrary pixel units $\pm \text{SE}$, $n = 5$ for each condition. Statistical significance was determined using Student's *t* test analysis; $*P \leq 0.01$ for an increase in mucus index between control and ADA-deficient samples, $**P \leq 0.02$ for a decrease in mucus index between ADA-deficient samples and PEG-ADA-treated ADA-deficient samples.

after PEG-ADA enzyme therapy further suggested that the efficacy of this treatment was a consequence of lowering adenosine and 2'-deoxyadenosine levels. This was confirmed by examining the levels of ADA substrates in ADA-deficient lungs after PEG-ADA treatments (Fig. 7). The levels of adenosine in control lungs at day 18 were <0.2 nmol/mg protein, whereas adenosine levels in the lungs of ADA-deficient mice were elevated >20 -fold (6.3 nmol/mg protein). 2'-Deoxyadenosine was not detected in control lungs and was elevated to 0.05 nmol/mg protein in ADA-deficient lungs. Strikingly, 72 h after treatment with PEG-ADA, adenosine and 2'-deoxyadenosine levels were lowered to near control levels in ADA-deficient lungs. These studies demonstrated that PEG-ADA enzyme therapy could efficiently remove adenosine and 2'-deoxyadenosine from the lungs of ADA-deficient mice, and suggested that accumulations of these nucleosides may play a




Figure 7. PEG-ADA treatments reverse accumulations of adenosine and 2'-deoxyadenosine in the lungs of ADA-deficient mice. Adenosine and 2'-deoxyadenosine levels were quantitated in the lungs of 18-d-old control mice ($n = 5$) and ADA-deficient mice ($n = 4$), and 21-d-old ADA-deficient mice 3 d after treatment with PEG-ADA ($n = 4$). Mean values are given as nmol/mg protein $\pm \text{SE}$. Statistical significance was determined using Student's *t* test analysis; $*P \leq 0.002$. nd, not detectable at a minimal detection limit of 0.001 nmol/mg protein.

role in regulating the lung eosinophilia and mucus production seen.

Genetic Replacement of ADA Prevents Lung Metabolic Disturbances and the Development of Histopathologies. The results obtained using PEG-ADA provided compelling evidence that adenine metabolic disturbances were associated with the onset and progression of the pulmonary changes occurring in ADA-deficient mice. Therefore, we hypothesized that genetically providing an enriched source of ADA to these mice would prevent metabolic disturbances and pulmonary changes. To this end, we examined the status of lung structure, inflammation, and metabolic disturbances in ADA-deficient mice in which expression of ADA was specifically targeted to the forestomach (19). The forestomach was chosen because it is an enriched site of ADA production, and gene regulatory elements necessary for forestomach-specific expression were available (41). Transgenic expression of ADA in the forestomach of otherwise ADA-deficient mice (Fig. 8 e) prevented respiratory distress, allowing the animals to live a normal life span. Examination of lung histology revealed that these mice were comparable to control animals, and did not exhibit signs of abnormal alveogenesis, or increases in alveolar macrophages or eosinophils (Fig. 8, a-c; BALF data not shown). Correspondingly, adenosine and 2'-deoxyadenosine levels in the lungs of these animals were not significantly elevated (Fig. 8 d). Collectively, these data suggested that enriched expression of ADA in the forestomach of ADA-deficient mice could prevent the accumulation of adenosine and 2'-deoxyadenosine in the lung as well as pulmonary histopathologies and inflammation associated with these accumulations.

Discussion

Results presented in this study demonstrate that the metabolic disturbances associated with ADA deficiency in mice




Figure 8. Transgenic expression of ADA in the forestomach of ADA-deficient mice prevents adenosine and 2'-deoxyadenosine accumulation, lung inflammation, and lung histopathologies. (a) H&E-stained section of an 18-d-old control lung. (b) H&E-stained section of a 21-d-old ADA-deficient lung. (c) H&E-stained section of a 21-d-old ADA-deficient lung of a mouse expressing an ADA minigene in its forestomach. Bars, (a–c) 250 μ m. (d) Adenosine and 2'-deoxyadenosine levels were quantitated in the lungs of 21-d-old control, ADA-deficient, or ADA-deficient mice expressing ADA in their forestomach (forestomach rescue). Mean values are given as nmol/mg protein \pm SE; $n = 3$ for each. Statistical significance was determined using Student's *t* test analysis; * $P \leq 0.002$. nd, not detected at a minimal detection limit of 0.001 nmol/mg protein. (e) Zymogram analysis showing the level of ADA enzymatic activity in the lung (L), blood (Bi), and forestomach (FS) of 21-d-old control, ADA-deficient, and ADA-deficient mice expressing ADA in their forestomach. Purine nucleoside phosphorylase (PNP) was used as a positive control.

result in abnormal lung development and the promotion of lung inflammation and damage. ADA-deficient mice exhibited alveolar defects that were overcome by genetically restoring ADA enzymatic activity to these animals. In addition, lowering ADA substrates in the lung using enzyme therapy reversed lung eosinophilia and mucus production. The ADA substrates adenosine and 2'-deoxyadenosine both have potent cellular signaling properties, some of which have been implicated to play a role in lung inflammation. These mice will therefore serve as a useful *in vivo* model system in which to study the role of purinergic signaling in aspects of lung development and disease.

Defects in alveogenesis have been noted in mice deficient in various growth factor signaling pathways, including fibroblast growth factor (42), platelet-derived growth factor (43), and transforming growth factor β (44) signaling pathways. In addition, overexpression of cytokines such as IL-11 (45) and IL-13 (46) in the lungs of mice results in defects in alveogenesis. These findings suggest that this stage of lung development is influenced by complex signaling pathways. Developmental analysis of lung structure in ADA-deficient mice revealed a defect in alveolarization. This defect preceded the onset of lung inflammation. The pronounced elevations of adenosine in ADA-deficient lungs suggested that perturbations in adenosine signaling may play a role in the alveolar defect seen. Nothing is

known with regard to the expression of adenosine receptors during lung development, and examining the expression of adenosine receptors in normal and ADA-deficient lungs will help clarify the role of adenosine signaling during normal and abnormal alveogenesis.

ADA-deficient mice develop and succumb to severe pulmonary inflammation and lung damage by 3 wk of age (15). Characterization of the inflammation revealed a large accumulation of activated macrophages throughout the lungs and an infiltration of eosinophils around pulmonary blood vessels and bronchial airways. The inflammation was progressive, with no inflammation evident until postpartum day 10, after which lung inflammation increased in severity. This inflammation was associated with a pronounced increase in mucus production and a marked increase in lung adenosine levels. The observation that lowering adenosine levels improved pulmonary inflammation and mucus production suggested that adenosine may mediate these processes. Consistent with this suggestion is the extensive literature base showing that adenosine plays a role in inflammatory lung diseases such as asthma and chronic obstructive pulmonary disease (for a review, see reference 20). The exact functions that this signaling nucleoside plays in lung disease are not known, but they likely depend on the type of inflammatory cells present and the distribution of adenosine receptors on these cells. The abil-

ity to control adenosine levels in ADA-deficient mice using enzyme replacement therapy will provide a useful model for examining the influence of adenosine on different inflammatory cells *in vivo*.

Eosinophils have emerged as a major inflammatory cell type in asthma, and an increase in eosinophils is often observed in the lungs of asthmatics (47). These cells can release mediators that contribute to the airway damage often associated with asthma such as bronchial epithelial cell damage and the stimulation of mucus production (48, 49). The accumulation of eosinophils in the lungs of ADA-deficient mice may be responsible for the increased mucus production seen. This is supported by the observation that decreasing the number of eosinophils in the lungs of ADA-deficient mice using ADA enzyme therapy also resulted in decreased mucus production. Alternatively, the decreased mucus production may be a direct effect of lowering lung adenosine levels since adenosine signaling has been demonstrated to increase mucus secretion in a canine mucus model (50). Increased mucus production in ADA-deficient mice was not associated with an increase in IL-4 in the BALF, suggesting the production of mucus in this model was not IL-4 dependent. Whether the mucus production was mediated by other Th2 cytokines such as IL-13 or IL-9, or by eosinophil-derived mediators or adenosine itself, remains to be determined.

The involvement of adenosine signaling in eosinophil biology has been demonstrated. The A3 adenosine receptor is expressed on human eosinophils that accumulate in the lung (23), and engagement of this receptor on eosinophils is thought to mediate the release of Ca^{2+} from intracellular stores (29), inhibit superoxide release (28), and inhibit eosinophil chemotaxis, which may serve a pro- or anti-inflammatory role (23, 27). Whether or not the A3 receptor is expressed in murine eosinophils and in the lungs of ADA-deficient mice is currently under investigation. However, the large increase in lung eosinophils in ADA-deficient mice and the ability to rapidly reverse this eosinophilia by lowering adenosine concentrations suggest that adenosine signaling may be mediating the lung eosinophilia occurring in these mice.

In addition to an increase in eosinophils, the number and activation of alveolar macrophages were greatly increased in the lungs of ADA-deficient mice. Engagement of adenosine receptors on macrophages elicits both pro- and anti-inflammatory events, including the inhibition of TNF- α expression (51, 52) and nitric oxide production (51), increased production of IL-10 (51), increased differentiation of monocytes into macrophages (31, 32, 53), increased rates of phagocytosis (32), and stimulation of giant cell formation (30). Therefore, the increased number and activity of alveolar macrophages and giant cells in ADA-deficient mice may result from aberrant adenosine signaling brought about by persistent elevations in lung adenosine levels. Activated macrophages can contribute to alveolar airway damage (54). The enlargement of the alveolar airways in ADA-deficient mice is associated with a defect in alveogenesis. However, the enlargement of these airways is pro-

gressive from postpartum day 15 to 18, suggesting that damage to these airways is also occurring. The large number of activated macrophages found in the alveolar airways of these mice may contribute to the increased damage seen. The determination of proteolytic enzyme production by these macrophages and the influence of adenosine signaling on this process will help clarify the role of activated macrophages in this model. The number of macrophages found in the lungs of ADA-deficient mice was not altered 72 h after PEG-ADA treatments, nor was there any improvement in the alveolar damage seen. The persistence of macrophages may indicate that these cells are actively involved in the clearance of cellular debris resultant of the severe eosinophilia and tissue damage seen. The ability to control adenosine levels using varying doses of PEG-ADA will provide a useful tool to explore the involvement of adenosine signaling in both eosinophil and macrophage function.

ADA deficiency in humans is most commonly associated with a combined immunodeficiency (7). However, additional phenotypes have been described, including bone and renal abnormalities (12), hepatocellular damage (13), neurological disorders, and pulmonary insufficiencies (7). Although the treatment of ADA-deficient patients with PEG-ADA has rapid beneficial effects on some of these phenotypes (14, 55), it is still not clear whether they are a primary consequence of the ADA deficiency. Here, we demonstrate that ADA enzyme therapy can rapidly reverse respiratory distress in ADA-deficient mice in conjunction with lowering lung adenosine and 2'-deoxyadenosine levels, suggesting that the respiratory distress seen in this model is a direct consequence of ADA deficiency. This suggestion is supported by observations that the ADA enzyme therapy protocol used did not improve the immune status in these animals. Pulmonary insufficiency is common in ADA-deficient patients, and these insufficiencies are most often attributed to bacterial or viral pneumonia that arises from a compromised immune system. However, in many cases of interstitial pneumonia an organism cannot be isolated (7). Our observations in ADA-deficient mice suggest that it is possible that the adenine metabolic disturbances in ADA-deficient patients may directly contribute to the pulmonary insufficiency occurring in this population.

Some ADA-deficient patients have been shown to have elevated levels of IgE, eosinophilia, and an increased incidence of asthma (8, 38, 39). These individuals are typically patients with delayed or late onset ADA deficiency and thus have milder forms of immunodeficiency (7, 8). ADA-deficient mice exhibited an increase in serum IgE, eosinophilia, and developed lung inflammatory changes, suggesting that they resemble patients with a less severe form of ADA deficiency. Consistent with this is the observation that the immunodeficiency seen in ADA-deficient mice is not as severe as that seen in completely ADA-deficient humans (15). However, the immunodeficiency seen in these animals must be considered when trying to understand the nature of the lung inflammation seen. Lung eosinophilia is often associated with a Th2 cytokine profile (56). However, there was not a robust Th2 cytokine profile in BALF

collected from ADA-deficient mice. Since Th2 cytokines such as IL-4 are produced largely by CD4 T cells, the immunodeficiency seen in ADA-deficient mice may impact the relative capability to generate Th2 cytokines. Alternatively, the absence of a robust Th2 response suggests that other signaling pathways are involved in mediating the lung eosinophilia seen.

In conclusion, by deleting the enzyme responsible for controlling the levels of adenosine and 2'-deoxyadenosine, we have generated animals that exhibit adenine metabolic disturbances in association with alveolar defects and the development of severe pulmonary inflammation. Lung eosinophilia was reduced and the animals were rescued from respiratory distress by lowering adenosine and 2'-deoxyadenosine levels using ADA enzyme therapy. Although 2'-deoxyadenosine-mediated effects on this phenotype cannot be ruled out, there is substantial evidence to suggest adenosine signaling may be playing an important role in the type of inflammation and tissue damage seen (20). Defining the adenosine receptors expressed on eosinophils, macrophages, and in the lungs of ADA-deficient mice, and using pharmacological and genetic technologies to assess their function, will help us to understand how adenosine influences lung inflammation in this model. This may in turn help guide new therapies for the treatment of lung conditions in which eosinophils and macrophages are thought to mediate damage, including asthma, idiopathic eosinophilic lung inflammation, chronic obstructive pulmonary disease, and emphysema. The correlation of increased lung adenosine and asthma (21) and the ability to relieve lung eosinophilia in mice by lowering adenosine levels raise the possibility that ADA enzyme therapy may be beneficial in the treatment of eosinophilic lung inflammation. Using ADA-deficient mice as a testing ground to understand the basis for adenosine-dependent lung eosinophilia will aid in evaluating the efficacy of such therapies.

We thank Drs. Michael S. Hershfield and Giuseppe N. Colasurdo for their helpful discussions and review of the manuscript.

This work was supported by National Institutes of Health grants AI43572 and HL61888 (both to M.R. Blackburn), DK46207, and DK54443 (R.E. Kellems), and Texas Higher Education Coordinating Board Applied Technology Grant 011618-060 (M.R. Blackburn). Funds for this work were also provided by the Mayo Foundation (J.J. Lee).

Submitted: 24 August 1999

Revised: 3 May 2000

Accepted: 8 May 2000

References

- Frederiksen, S. 1966. Specificity of adenosine deaminase toward adenosine and 2'-deoxyadenosine analogues. *Arch. Biochem. Biophys.* 113:383-388.
- Olah, M.E., and G.L. Stiles. 1995. Adenosine receptor subtypes: characterization and therapeutic regulation. *Annu. Rev. Pharmacol. Toxicol.* 35:581-606.
- Hershfield, M.S., N.M. Kredich, D.R. Ownby, H. Ownby, and R. Buckley. 1979. In vivo inactivation of erythrocyte S-adenosylhomocysteine hydrolase by 2'-deoxyadenosine in adenosine deaminase-deficient patients. *J. Clin. Invest.* 63: 807-811.
- Benveniste, P., W. Zhu, and A. Cohen. 1995. Interference with thymocyte differentiation by an inhibitor of S-adenosylhomocysteine hydrolase. *J. Immunol.* 155:536-544.
- Benveniste, P., and A. Cohen. 1995. p53 expression is required for thymocyte apoptosis induced by adenosine deaminase deficiency. *Proc. Natl. Acad. Sci. USA.* 92:8373-8377.
- Liu, X., C.N. Kim, J. Yang, R. Jemmerson, and X. Wang. 1996. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. *Cell.* 86:147-157.
- Hershfield, M.S., and B.S. Mitchell. 1995. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. In *The Metabolic and Molecular Basis of Inherited Disease*. 7th ed., Vol. 1. C.R. Scriver, A.L. Beaudet, W.S. Sly, and D. Valle, editors. McGraw-Hill, Inc., New York. 1725-1768.
- Hirschhorn, R. 1999. Immunodeficiency disease due to deficiency of adenosine deaminase. In *Primary Immunodeficiency Disease: A Molecular and Genetic Approach*. H.D. Ochs, C.I.E. Smith, and J.M. Puck, editors. Oxford University Press, New York. 121-138.
- Donofrio, J., M.S. Coleman, J.J. Hutton, A. Daoud, B. Lampkin, and J. Dyminski. 1978. Overproduction of adenine deoxynucleosides and deoxynucleotides in adenosine deaminase deficiency with severe combined immunodeficiency disease. *J. Clin. Invest.* 62:884-887.
- Kizaki, H., K. Suzuki, T. Tadakuma, and Y. Ishimura. 1990. Adenosine receptor-mediated accumulation of cyclic AMP-induced T-lymphocyte death through internucleosomal DNA cleavage. *J. Biol. Chem.* 265:5280-5284.
- Huang, S., S. Apasov, M. Koshiba, and M. Sitkovsky. 1997. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. *Blood.* 90:1600-1610.
- Ratech, H., M.A. Greco, G. Gallo, D.L. Rimoin, H. Kamino, and R. Hirschhorn. 1985. Pathologic findings in adenosine deaminase-deficient severe combined immunodeficiency. I. Kidney, adrenal, and chondro-osseous tissue alterations. *Am. J. Pathol.* 120:157-169.
- Bollinger, M.E., F.X. Arredondo-Vega, I. Santisteban, K. Schwarz, M.S. Hershfield, and H.M. Lederman. 1996. Brief report: hepatic dysfunction as a complication of adenosine deaminase deficiency. *N. Engl. J. Med.* 334:1367-1371.
- Hirschhorn, R., P.S. Paageorgiou, H.H. Kesarwala, and L.T. Taft. 1980. Amelioration of neurologic abnormalities after "enzyme replacement" in adenosine deaminase deficiency. *N. Engl. J. Med.* 303:377-380.
- Blackburn, M.R., S.K. Datta, and R.E. Kellems. 1998. Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency. *J. Biol. Chem.* 273:5093-5100.
- Wakamiya, M., M.R. Blackburn, R. Jurecic, M.J. McArthur, R.S. Geske, J. Cartwright, Jr., K. Mitani, S. Vaishnav, J.W. Belmont, R.E. Kellems, et al. 1995. Disruption of the adenosine deaminase gene causes hepatocellular impairment and perinatal lethality in mice. *Proc. Natl. Acad. Sci. USA.* 92: 3673-3677.
- Migchielsen, A.A., M.L. Breuer, M.A. van Roon, H. te Riele, C. Zurcher, F. Ossendorp, S. Toutain, M.S. Hershfield, A. Berns, and D. Valerio. 1995. Adenosine-deaminase-deficient mice die perinatally and exhibit liver-cell degeneration,

- atelectasis and small intestinal cell death. *Nat. Genet.* 10:279–287.
18. Blackburn, M.R., M. Wakamiya, C.T. Caskey, and R.E. Kellems. 1995. Tissue-specific rescue suggests that placental adenosine deaminase is important for fetal development in mice. *J. Biol. Chem.* 270:23891–23894.
 19. Blackburn, M.R., S.K. Datta, M. Wakamiya, B.S. Vartabedian, and R.E. Kellems. 1996. Metabolic and immunologic consequences of limited adenosine deaminase expression in mice. *J. Biol. Chem.* 271:15203–15210.
 20. Jacobson, M.A., and T.R. Bai. 1997. The role of adenosine in asthma. In *Purinergic Approaches in Experimental Therapeutics*. K.A. Jacobson and M.F. Jarvis, editors. Wiley-Liss, Inc., Danvers, MA. 315–331.
 21. Driver, A.G., C.A. Kukoly, S. Ali, and S.J. Mustafa. 1993. Adenosine in bronchoalveolar lavage fluid in asthma. *Am. Rev. Respir. Dis.* 148:91–97.
 22. Cushley, M.J., A.E. Tattersfield, and S.T. Holgate. 1983. Inhaled adenosine and guanosine on airway resistance in normal and asthmatic subjects. *Br. J. Clin. Pharmacol.* 15:161–165.
 23. Walker, B.A., M.A. Jacobson, D.A. Knight, C.A. Salvatore, T. Weir, D. Zhou, and T.R. Bai. 1997. Adenosine A3 receptor expression and function in eosinophils. *Am. J. Respir. Cell Mol. Biol.* 16:531–537.
 24. Barnes, P.J. 1997. Current therapies for asthma. Promise and limitations. *Chest.* 111:17S–26S.
 25. Marquardt, D.L., C.W. Parker, and T.J. Sullivan. 1978. Potentiation of mast cell mediator release by adenosine. *J. Immunol.* 120:871–878.
 26. Fozard, J.R., H.J. Pfannkuche, and H.J. Schuurman. 1996. Mast cell degranulation following adenosine A3 receptor activation in rats. *Eur. J. Pharmacol.* 298:293–297.
 27. Knight, D., X. Zheng, C. Rocchini, M. Jacobson, T. Bai, and B. Walker. 1997. Adenosine A3 receptor stimulation inhibits migration of human eosinophils. *J. Leukoc. Biol.* 62:465–468.
 28. Ezeamuzie, C.I., and E. Philips. 1999. Adenosine A3 receptors on human eosinophils mediate inhibition of degranulation and superoxide anion release. *Br. J. Pharmacol.* 127:188–194.
 29. Kohno, Y., X. Ji, S.D. Mawhorter, M. Koshiba, and K.A. Jacobson. 1996. Activation of A3 adenosine receptors on human eosinophils elevates intracellular calcium. *Blood.* 88:3569–3574.
 30. Merrill, J.T., C. Shen, D. Schreiber, D. Coffey, O. Zakharenko, R. Fisher, R.G. Lahita, J. Salmon, and B.N. Cronstein. 1997. Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: a mechanism for methotrexate-induced nodulosis in rheumatoid arthritis. *Arthritis Rheum.* 40:1308–1315.
 31. Najar, H.M., S. Ruhl, A.C. Bru-Capdeville, and J.H. Peters. 1990. Adenosine and its derivatives control human monocyte differentiation into highly accessory cells versus macrophages. *J. Leukoc. Biol.* 47:429–439.
 32. Eppell, B.A., A.M. Newell, and E.J. Brown. 1989. Adenosine receptors are expressed during differentiation of monocytes to macrophages in vitro. Implications for regulation of phagocytosis. *J. Immunol.* 143:4141–4145.
 33. Revan, S., M.C. Montesinos, D. Naime, S. Landau, and B.N. Cronstein. 1996. Adenosine A2 receptor occupancy regulates stimulated neutrophil function via activation of a serine/threonine protein phosphatase. *J. Biol. Chem.* 271:17114–17118.
 34. Walker, B.A., C. Rocchini, R.H. Boone, S. Ip, and M.A. Jacobson. 1997. Adenosine A2a receptor activation delays apoptosis in human neutrophils. *J. Immunol.* 158:2926–2931.
 35. Lee, J.J., M.P. McGarry, S.C. Farmer, K.L. Denzler, K.A. Larson, P.E. Carrigan, I.E. Brenneise, M.A. Horton, A. Haczk, E.W. Gelfand, et al. 1997. Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma. *J. Exp. Med.* 185:2143–2156.
 36. Escolar, J.D., B. Gallego, C. Tejero, and M.A. Escolar. 1994. Changes occurring with increasing age in the rat lung: morphometrical study. *Anat. Rec.* 239:287–296.
 37. Knudsen, T.B., R.S. Winters, S.K. Otey, M.R. Blackburn, M.J. Airhart, J.K. Church, and R.G. Skalko. 1992. Effects of (R)-deoxycytoformycin (pentostatin) on intrauterine nucleoside catabolism and embryo viability in the pregnant mouse. *Teratology.* 45:91–103.
 38. Levy, Y., M.S. Hershfield, C. Fernandez-Mejia, S.H. Polmar, D. Scudieri, M. Berger, and R.U. Sorensen. 1988. Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase. *J. Pediatr.* 113:312–317.
 39. Shovlin, C.L., J.M. Hughes, H.A. Simmonds, L. Fairbanks, S. Deacock, R. Lechler, I. Roberts, and A.D. Webster. 1993. Adult presentation of adenosine deaminase deficiency. *Lancet.* 341:1471.
 40. Hershfield, M.S., S. Chaffee, and R.U. Sorensen. 1993. Enzyme replacement therapy with polyethylene glycol-adenosine deaminase in adenosine deaminase deficiency: overview and case reports of three patients, including two now receiving gene therapy. *Pediatr. Res.* 33:S42–S48.
 41. Xu, P.A., J.H. Winston, S.K. Datta, and R.E. Kellems. 1999. Regulation of forestomach-specific expression of the murine adenosine deaminase gene. *J. Biol. Chem.* 274:10316–10323.
 42. Weinstein, M., X. Xu, K. Ohyama, and C.X. Deng. 1998. FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung. *Development.* 125:3615–3623.
 43. Bostrom, H., K. Willetts, M. Pekny, P. Leveen, P. Lindahl, H. Hedstrand, M. Pekna, M. Hellstrom, S. Gebre-Medhin, M. Schalling, et al. 1996. PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis. *Cell.* 85:863–873.
 44. Kaartinen, V., J.W. Voncken, C. Shuler, D. Warburton, D. Bu, N. Heisterkamp, and J. Groffen. 1995. Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction. *Nat. Genet.* 11:415–421.
 45. Ray, P., W. Tang, P. Wang, R. Homer, C. Kuhn III, R.A. Flavell, and J.A. Elias. 1997. Regulated overexpression of interleukin 11 in the lung. Use to dissociate development-dependent and -independent phenotypes. *J. Clin. Invest.* 100:2501–2511.
 46. Zhu, Z., R.J. Homer, Z. Wang, Q. Chen, G.P. Geba, J. Wang, Y. Zhang, and J.A. Elias. 1999. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eosinophil production. *J. Clin. Invest.* 103:779–788.
 47. Streck, M.K., and A.R. Leff. 1997. Eosinophils. In *Asthma*. P.J. Barnes, A.R. Leff, M.M. Grunstein, and A.J. Woolcock, editors. Vol. 1. Lippincott-Raven, Philadelphia. 353–365.
 48. Leff, A.R. 1994. Inflammatory mediation of airway hyperresponsiveness by peripheral blood granulocytes. The case for the eosinophil. *Chest.* 106:1202–1208.

49. Gleich, G.J. 1990. The eosinophil and bronchial asthma: current understanding. *J. Allergy Clin. Immunol.* 85:422–436.
50. Johnson, H.G., and M.L. McNee. 1985. Adenosine-induced secretion in the canine trachea: modification by methylxanthines and adenosine derivatives. *Br. J. Pharmacol.* 86:63–67.
51. Hasko, G., C. Szabo, Z.H. Nemeth, V. Kvetan, S.M. Pastores, and E.S. Vizi. 1996. Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. *J. Immunol.* 157:4634–4640.
52. Sajjadi, F.G., K. Takabayashi, A.C. Foster, R.C. Domingo, and G.S. Firestein. 1996. Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. *J. Immunol.* 156:3435–3442.
53. Salmon, J.E., N. Brogle, C. Brownlie, J.C. Edberg, R.P. Kimberly, B.X. Chen, and B.F. Erlanger. 1993. Human mononuclear phagocytes express adenosine A1 receptors. A novel mechanism for differential regulation of Fc gamma receptor function. *J. Immunol.* 151:2775–2785.
54. Abboud, R.T., A.F. Ofulue, R.H. Sansores, and N.L. Muller. 1998. Relationship of alveolar macrophage plasminogen activator and elastase activities to lung function and CT evidence of emphysema. *Chest.* 113:1257–1263.
55. Bollinger, M.E., F.X. Arredondo-Vega, I. Santisteban, K. Schwarz, M.S. Hershfield, and H.M. Lederman. 1996. Hepatic dysfunction as a complication of adenosine deaminase deficiency. *N. Engl. J. Med.* 334:1367–1371.
56. Barnes, P.J., S.T. Holgate, L.A. Laitinen, and R. Pauwels. 1995. Asthma mechanisms, determinants of severity and treatment: the role of nedocromil sodium. Report of a workshop held in Whistler, British Columbia, Canada, 18–19 May 1995. *Clin. Exp. Allergy.* 25:771–787.